BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30

• 

  Colossal and U Melbourne Hope to Make Thylacine Lore Reality with CRISPR

  Working to undo the sins of the past, Colossal Biosciences and the University of Melbourne are attempting to bring back the Tasmanian tiger in a project that could have big implications for human health.

  November 3, 2022

   · 

  5 min read

   · 

  Abbey Glasure
• 

  Policy

  Cassava Files Defamation Suit against Short Sellers Linked to Data Manipulation Allegations - Updated

  Cassava filed a lawsuit in federal court against individuals linked to a Citizen’s Petition filed with the FDA that raised concerns about data manipulation in a clinical study of simufilam.

  November 3, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Rubius Therapeutics Cuts 84% of Workforce, Explores Sale and Merger Options

  Rubius Therapeutics plans to initiate a large restructuring initiative, which includes laying off 84% of its staff and a possible sale, the company announced Wednesday.

  November 3, 2022

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Regeneron Pulls the Plug on Osteoarthritis and Cat Allergy Therapies

  Regeneron called it quits on an experimental osteoarthritis pain treatment that has raised safety flags and an experimental antibody for cat-allergic asthma.

  November 3, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Moderna Loses AstraZeneca’s Support in IL-12 Program; Must Defend Arbutus Suit

  Moderna is dropping an IL-12 program in autoimmune disorders after AstraZeneca returned the rights, the mRNA leader announced Thursday in its third quarter filing.

  November 3, 2022

   · 

  1 min read

   · 

  Mark Terry
• 

  Business

  Movers & Shakers: Ambrx, ADC Therapeutics, ImmunoGen and More get New C-Suites

  The executive shuffle continues across the biopharma industry as companies shore up leadership needs with these Movers & Shakers.

  November 3, 2022

   · 

  6 min read

   · 

  Alex Keown
• 

  Drug Development

  Emalex Closes $250M Series D to Fund Phase III Trial in Tourette Syndrome

  Emalex Biosciences closed a Series D funding round Thursday counting $250 million in earnings, much of which will bankroll a Phase III trial of ecopipam for Tourette syndrome.

  November 3, 2022

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Exelixis Inks Third Collaboration Deal in a Week, This Time with Catalent

  Exelixis has inked a licensing agreement with Catalent to gain access to three of Catalent’s target programs with antibody and ADC candidates, the companies announced Thursday.

  November 3, 2022

   · 

  2 min read

   · 

  Rosemary Scott
• 

  Drug Development

  Roche’s Ocrevus Shines in Relapsing-Remitting MS, Safety Studies

  Genentech made approximately 35 presentations at ECTRIMS involving blockbuster MS drug Ocrevus drug, with a focus on relapsing-remitting MS and continuing safety studies.

  November 3, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Abeona to Ride Demonstrative Phase III Data to BLA in Rare Tissue Disease

  Abeona Therapeutics will head to the FDA next year for the potential approval of its experimental recessive dystrophic epidermolysis bullosa (RDEB) therapy following positive Phase III data.

  November 3, 2022

   · 

  2 min read

   · 

  Alex Keown